Specific genes linked to an increased risk for cardiovascular disease also increase the risk for Alzheimer’s disease, according to results of a large genetic study. Researchers also found that managing the levels of lipids in the blood, such as cholesterol and triglycerides, may reduce the risk of Alzheimer’s in…
News
Roughly 20 percent of Alzheimer’s disease patients in Finland combine sleeping pills (benzodiazepines) with strong painkillers (opioids), a practice that has been associated with serious risks, a study shows. These findings highlight the need for therapeutic strategies that reduce the unnecessary co-use of these compounds, according to the authors of…
A new treatment using focused ultrasound to treat early-stage Alzheimer’s disease was successfully administered to a patient. The treatment, which involves incisionless surgery and no pharmaceuticals, is part of a worldwide Phase 2 trial. The trial (NCT03671889) is underway and recruiting up to 10 participants — men or…
Use of an active DNA vaccine in mice with hallmarks of Alzheimer’s disease significantly lowered the toxic accumulation of amyloid plaques and tau without triggering severe brain swelling — a damaging complication seen in earlier antibody treatments. These results may pave the way to test this DNA vaccine in clinical…
Deep learning, a type of artificial intelligence, used brain imaging scans to predict — years in advance and with nearly 100% sensitivity — patients who eventually developed Alzheimer’s disease, a study reports. The study, “A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using 18F-FDG PET of…
Improved Brain Immunotherapy Delivery Strategy Uses Brain’s Natural Plumbing System, Study Reports
A new approach for delivering antibody-based therapeutics to the brain by exploiting the fluid surrounding the brain’s blood vessels was proposed in a recent preclinical study. This improved brain immunotherapy delivery strategy has implications for treating diseases of the brain and spinal cord, including Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis…
Essential oils derived from different plant species have revealed encouraging clinical and preclinical results to reverse cognitive and memory impairments in Alzheimer’s disease, a review study has found. The study, “Essential Oils as Treatment Strategy for Alzheimerʼs Disease: Current and Future Perspectives,” was published in the journal…
Alector’s candidate immune system-targeting therapy for Alzheimer’s disease, called AL002, will be evaluated for safety and tolerability in a first Phase 1 clinical trial, the company announced. AL002 is an antibody that targets and activates TREM2 (triggering receptor expressed on myeloid cells 2), a receptor selectively expressed on microglia — a group…
People with dementia, including those with Alzheimer’s disease, often are also living with one or more other chronic diseases that significantly impact their quality of life, according to a new study. The study, “The impact of comorbidity on the quality of life of people with dementia: findings from the…
Beta-amyloid’s Key Role in Alzheimer’s Toxic Clumps and Need for Personalized Medicine Focus of Talk
Increasing evidence places beta-amyloid aggregates at the center of the toxic protein clumps and neuroinflammation that drive Alzheimer’s, two experts in this disease said, and a personalized, combination treatment likely will be the best way of helping patients. These insights were shared at a recent Key Opinion Leader luncheon meeting,…
Recent Posts
- Researchers explore surgical treatment’s potential in Alzheimer’s March 2, 2026
- FDA fast-tracks expanded home injections for Alzheimer’s drug Leqembi February 2, 2026
- FDA decision on AXS-05 for Alzheimer’s agitation expected April 30 January 6, 2026
- Oral semaglutide fails to slow Alzheimer’s in pair of clinical trials December 2, 2025
- Canada gives conditional OK to early Alzheimer’s drug Leqembi November 4, 2025